MX2022012209A - Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion. - Google Patents

Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion.

Info

Publication number
MX2022012209A
MX2022012209A MX2022012209A MX2022012209A MX2022012209A MX 2022012209 A MX2022012209 A MX 2022012209A MX 2022012209 A MX2022012209 A MX 2022012209A MX 2022012209 A MX2022012209 A MX 2022012209A MX 2022012209 A MX2022012209 A MX 2022012209A
Authority
MX
Mexico
Prior art keywords
expression vector
factor
application
human nuclear
nucleic acid
Prior art date
Application number
MX2022012209A
Other languages
English (en)
Inventor
Bin Li
Ting Liu
Original Assignee
Wuhan Neurophth Biotechnology Ltd Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Neurophth Biotechnology Ltd Company filed Critical Wuhan Neurophth Biotechnology Ltd Company
Publication of MX2022012209A publication Critical patent/MX2022012209A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Se proporciona un ácido nucleico que codifica una proteína del factor 2 relacionado con el factor nuclear humano E2 (Nrf2) y una secuencia de nucleótidos del ácido nucleico. También se proporciona un vector de expresión recombinante que contiene el ácido nucleico y un transformante que introduce el ácido nucleico en un hospedador.
MX2022012209A 2020-03-30 2020-03-30 Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion. MX2022012209A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/082162 WO2021195876A1 (zh) 2020-03-30 2020-03-30 一种人核因子e2相关因子2的表达载体及其应用

Publications (1)

Publication Number Publication Date
MX2022012209A true MX2022012209A (es) 2022-10-27

Family

ID=77927115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012209A MX2022012209A (es) 2020-03-30 2020-03-30 Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion.

Country Status (10)

Country Link
US (1) US20240209391A1 (es)
EP (1) EP4163375A4 (es)
JP (1) JP2023528139A (es)
KR (1) KR20230015891A (es)
CN (1) CN115279906B (es)
AU (1) AU2020440834A1 (es)
BR (1) BR112022018193A2 (es)
CA (1) CA3173999A1 (es)
MX (1) MX2022012209A (es)
WO (1) WO2021195876A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116286837B (zh) * 2021-12-21 2026-04-28 武汉纽福斯生物科技有限公司 编码人核因子e2相关因子2的核酸分子、表达载体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
MXPA06006980A (es) * 2003-12-22 2006-12-14 Alcon Inc Agentes para tratamiento de retinopatia glaucomatosa y neuropatia optica.
WO2014058982A2 (en) * 2012-10-10 2014-04-17 Temple University Of The Commonwealth System Of Higher Education Nuclear factor-erythroid 2 related factor 2 (nrf2) biosensors and modulators of nrf2
KR20170055482A (ko) * 2014-09-10 2017-05-19 다이이찌 산쿄 가부시키가이샤 안질환 치료용 및 예방용 서방성 의약 조성물
WO2018200542A1 (en) * 2017-04-24 2018-11-01 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
CN109055428A (zh) * 2018-09-19 2018-12-21 上海市第人民医院 一种重组腺相关病毒载体及其制备方法与应用

Also Published As

Publication number Publication date
US20240209391A1 (en) 2024-06-27
CN115279906B (zh) 2024-08-06
EP4163375A4 (en) 2024-01-03
CN115279906A (zh) 2022-11-01
AU2020440834A1 (en) 2022-09-22
JP2023528139A (ja) 2023-07-04
CA3173999A1 (en) 2021-10-07
EP4163375A1 (en) 2023-04-12
KR20230015891A (ko) 2023-01-31
WO2021195876A1 (zh) 2021-10-07
BR112022018193A2 (pt) 2022-10-25

Similar Documents

Publication Publication Date Title
IL86480A (en) Recombinant dna coding for human proapolipoprotein a-1,expression vectors containing it and cells transformed by said expression vector
BR9813608A (pt) Polipeptìdeo isolado, sequências de ácido nucleico isolado e mutante, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, processos para produzir uma sequência de ácido nucleico mutante, para produzir um polipeptìdeo, para produzir um mutante de uma célula originária e para produzir uma proteìna, e, célula mutante
ES8500325A1 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
MX9206041A (es) Proceso para producir interferon inmune humano.
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
UA88138C2 (en) EXPRESSING VECTORS, CONTAINING IE2-PROMOTER mCMV
WO2002097038A3 (en) Chemokine beta-1 fusion proteins
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
ZA202300378B (en) Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
BR9811865A (pt) Isolamento de um novo gene de fator de senescência, p23
ES2058486T3 (es) Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis.
ZA202304029B (en) Cxcl9 and variants thereof for immunotherapy of cancer diseases
MX2022012209A (es) Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion.
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
DK0817858T3 (da) Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
MY209502A (en) N-terminal extension sequence for expression of recombinant therapeutic peptides
MX2024008847A (es) Vector viral de orthopox recombinante que codifica proteinas inmunoestimuladoras para el tratamiento del cancer.
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen